Tags

Type your tag names separated by a space and hit enter

Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
In Vivo. 2020 Jun; 34(3 Suppl):1597-1602.V

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortunately, the antiviral drugs commonly used in clinical practice to treat viral infections, are not applicable to SARS-Cov-2 and no vaccine is available. Thus, it is extremely necessary to identify new drugs suitable for the treatment of the 2019-nCoV outbreak. Different preclinical studies conducted on other coronaviruses suggested that promising clinical outcomes for 2019-nCoV should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. Moreover, clinical trials with these suitable drugs should be performed on patients affected by SARS-Cov-2 to prove their efficacy and safety. Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease.

Authors+Show Affiliations

Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - "Fondazione G.Pascale", Naples, Italy s.bimonte@istitutotumori.na.it.Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.Melanoma and Sarcoma Surgery Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - "Fondazione G.Pascale", Naples, Italy.Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - "Fondazione G.Pascale", Naples, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32503817

Citation

Bimonte, Sabrina, et al. "Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research." In Vivo (Athens, Greece), vol. 34, no. 3 Suppl, 2020, pp. 1597-1602.
Bimonte S, Crispo A, Amore A, et al. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. In Vivo. 2020;34(3 Suppl):1597-1602.
Bimonte, S., Crispo, A., Amore, A., Celentano, E., Cuomo, A., & Cascella, M. (2020). Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. In Vivo (Athens, Greece), 34(3 Suppl), 1597-1602. https://doi.org/10.21873/invivo.11949
Bimonte S, et al. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. In Vivo. 2020;34(3 Suppl):1597-1602. PubMed PMID: 32503817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. AU - Bimonte,Sabrina, AU - Crispo,Anna, AU - Amore,Alfonso, AU - Celentano,Egidio, AU - Cuomo,Arturo, AU - Cascella,Marco, PY - 2020/04/23/received PY - 2020/05/13/revised PY - 2020/05/16/accepted PY - 2020/6/7/entrez PY - 2020/6/7/pubmed PY - 2020/6/23/medline KW - COVID-19 KW - SARS-Cov-2 KW - antiviral drugs KW - coronaviruses KW - review KW - tocilizumab KW - virus SP - 1597 EP - 1602 JF - In vivo (Athens, Greece) JO - In Vivo VL - 34 IS - 3 Suppl N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortunately, the antiviral drugs commonly used in clinical practice to treat viral infections, are not applicable to SARS-Cov-2 and no vaccine is available. Thus, it is extremely necessary to identify new drugs suitable for the treatment of the 2019-nCoV outbreak. Different preclinical studies conducted on other coronaviruses suggested that promising clinical outcomes for 2019-nCoV should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. Moreover, clinical trials with these suitable drugs should be performed on patients affected by SARS-Cov-2 to prove their efficacy and safety. Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease. SN - 1791-7549 UR - https://www.unboundmedicine.com/medline/citation/32503817/Potential_Antiviral_Drugs_for_SARS_Cov_2_Treatment:_Preclinical_Findings_and_Ongoing_Clinical_Research_ L2 - http://iv.iiarjournals.org/cgi/pmidlookup?view=long&pmid=32503817 DB - PRIME DP - Unbound Medicine ER -